BellaSeno expands breast scaffold trial to 30 patients after positive two-year results
Materials
Originally reported by 3D Printing Industry
German medical startup BellaSeno has enrolled 30 patients across two Australian clinical trials of its resorbable polycaprolactone breast scaffold. The cohort comprises 19 patients from a first-in-human safety study conducted from 2021 to 2023, and 11 patients from a pivotal trial launched in January 2026. The company expects the total patient count to exceed 60 by the end of August. Two-year results presented at The Aesthetic MEET 2026 showed no scaffold-related complications, no capsular contracture, infections, or calcifications, and a mean breast volume retention of 83%. The scaffolds, made from medical-grade polycaprolactone, are implanted and seeded with the patient‘s own fat, then resorb over one to two years, leaving behind regenerated soft tissue.
The trial expansion places BellaSeno at the forefront of clinical-stage bioprinting for soft tissue reconstruction, addressing a decades-old problem with permanent silicone implants-capsular contracture, rupture, and implant-associated lymphoma. The scaffold’s full resorption eliminates the long-term liability of foreign-body devices. By contrast, competitor Conexeu Sciences listed on Nasdaq in May 2026 while still in the preclinical stage, without human safety data, highlighting how early the regenerative breast device field remains. BellaSeno’s dataset, though early, provides real human evidence that can support regulatory submissions in major markets if the pivotal trial confirms safety and volume retention. The company sits at the intersection of bioprinting and medical device development, with its technology pathway resembling that of resorbable polymer implants used in craniomaxillofacial surgery.
The practical question is whether the larger pivotal dataset-targeting regulatory-grade evidence-can replicate the early safety and volume-retention profile. BellaSeno must now accelerate patient enrollment under protocol and maintain follow-up discipline to build the evidence package required for clearance in markets like the EU and US. For now, the field remains a high-risk, high-reward frontier where a single data set can separate a clinical contender from a preclinical story.
Topics